Geoarchaeological Heritage of Kachchh Region, Gujarat, Western India: Geotourism Potentials

Thakkar, Adarsh; Jadeja, Jaypalsinh M.; Rajesh, S.; Chavan, Anil; Abhayan, G.S.; Bhandari, Subhash; Chauhan, Gaurav; Thakkar, M. G.

doi:10.1007/s12371-022-00748-y

Cited by 15 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Future research using the dataset will need to be done in accordance with standardized guidelines and with local ethics approval. Computer code has been deposited in GitHub and can be found at https://github.com/kith-pradhan/CovidBooster (copy archived at Thakkar, 2023a ) and https://github.com/kith-pradhan/CovidBooster4th (copy archived at Thakkar, 2023b ).…”

Section: Data Availabilitymentioning

confidence: 99%

Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial

Thakkar

Pradhan

Duva

et al. 2023

eLife

View full text Add to dashboard Cite

Background: Cancer patients show increased morbidity with COVID-19 and need effective immunization strategies. Many healthcare regulatory agencies recommend administering 'booster' doses of COVID-19 vaccines beyond the standard 2-dose series, for this group of patients. Therefore, studying the efficacy of these additional vaccine doses against SARS-CoV-2 and variants of concern is of utmost importance in this immunocompromised patient population.Methods: We conducted a prospective single arm clinical trial enrolling patients with cancer that had received two doses of mRNA or one dose of AD26.CoV2.S vaccine and administered a 3rd dose of mRNA vaccine. We further enrolled patients that had no or low responses to three mRNA COVID vaccines and assessed the efficacy of a 4th dose of mRNA vaccine. Efficacy was assessed by changes in anti-spike antibody, T-cell activity and neutralization activity were again assessed at baseline and 4 weeks.Results: We demonstrate that a 3rd dose of COVID-19 vaccine leads to seroconversion in 57% of patients that were seronegative after primary vaccination series. The immune response is durable as assessed by anti-S antibody titers, T-cell activity and neutralization activity against wild-type SARS-CoV2 and BA1.1.529 at 6 months of follow up. A subset of severely immunocompromised hematologic malignancy patients that were unable to mount an adequate immune response (titer <1000 AU/mL) after the 3rd dose and were treated with a 4th dose in a prospective clinical trial which led to adequate immune-boost in 67% of patients. Low baseline IgM levels and CD19 counts were associated with inadequate seroconversion. Booster doses induced limited neutralization activity against the Omicron variant.Conclusions: These results indicate that 3rd dose of COVID vaccine induces durable immunity in cancer patients and an additional dose can further stimulate immunity in a subset of patients with inadequate response.Funding: Leukemia lymphoma society, National Cancer Institute.Clinical trial identifier: NCT05016622.

show abstract

Section: Data Availabilitymentioning

confidence: 99%